<DOC>
	<DOCNO>NCT02217410</DOCNO>
	<brief_summary>The purpose study investigate safety , tolerability , pharmacokinetics ( PK ) potential CFZ533 replace calcineurin inhibitor ( CNI ) , provide similar rate acute rejection prophylaxis renal function de novo renal transplant population receive allograft standard criterion donor .</brief_summary>
	<brief_title>CCFZ533X2201 - PoC Study de Novo Renal Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Main Written inform consent must obtain assessment perform . Recipients kidney transplant heartbeating decease , live unrelated nonhuman leukocyte antigen ( HLA ) identical living relate donor . Recipients kidney cold ischemia time ( CIT ) &lt; 30 hour . Main Recipients organ nonheart beat donor . ABO incompatible complementdependent lymphocytotoxic ( CDC ) crossmatch positive transplant . Subjects receive second kidney allograft , unless first allograft lose due surgical complication . Subjects high immunological risk rejection Subjects risk tuberculosis ( TB ) Subject severe systemic infection , current within two week prior randomization/enrollment . Any additional contraindication use tacrolimus mycophenolate mofetil accord national labeling information product ( see local product label ) . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>renal , de novo ,</keyword>
</DOC>